Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis.
Yahagi K, Kolodgie FD, Otsuka F, Finn AV, Davis HR, Joner M, Virmani R.
Nat Rev Cardiol. 2016 Feb;13(2):79-98. doi: 10.1038/nrcardio.2015.164. Epub 2015 Oct 27.
Long-Term Results After Drug-Eluting Versus Bare-Metal Stent Implantation in Saphenous Vein Grafts: Randomized Controlled Trial.
Fahrni G, Farah A, Engstrøm T, Galatius S, Eberli F, Rickenbacher P, Conen D, Mueller C, Pfister O, Twerenbold R, Coslovsky M, Cattaneo M, Kaiser C, Mangner N, Schuler G, Pfisterer M, Möbius-Winkler S, Jeger RV; BASKET‐SAVAGE‐Investigators*.
J Am Heart Assoc. 2020 Oct 20;9(20):e017434. doi: 10.1161/JAHA.120.017434. Epub 2020 Oct 9.
Use of drug-eluting stents in saphenous vein aortocoronary bypass graft lesions: a critical appraisal.
Brilakis ES, Saeed B, Banerjee S.
J Interv Cardiol. 2008 Apr;21(2):151-7. doi: 10.1111/j.1540-8183.2007.00341.x. Epub 2008 Feb 28.
Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial.
Ali ZA, Maehara A, Généreux P, Shlofmitz RA, Fabbiocchi F, Nazif TM, Guagliumi G, Meraj PM, Alfonso F, Samady H, Akasaka T, Carlson EB, Leesar MA, Matsumura M, Ozan MO, Mintz GS, Ben-Yehuda O, Stone GW; ILUMIEN III: OPTIMIZE PCI Investigators.
Lancet. 2016 Nov 26;388(10060):2618-2628. doi: 10.1016/S0140-6736(16)31922-5. Epub 2016 Oct 30.
Saphenous Vein Graft Aneurysm after Drug-Eluting Stent Implantation: Treatment by Covered Stent.
Papadopoulos K, Avraamides P.
Case Rep Cardiol. 2021 Nov 5;2021:2360804. doi: 10.1155/2021/2360804. eCollection 2021.
Three-Year Clinical and Angiographic Outcomes After Everolimus-Eluting Stent Implantation in Patients With a History of Coronary Artery Bypass Grafting.
Nomura T, Suzuki N, Takamura S, Kyono H, Kozuma K.
Int Heart J. 2016;57(2):158-66. doi: 10.1536/ihj.15-312. Epub 2016 Mar 11.
The impact of diabetes mellitus on long-term clinical outcomes after percutaneous coronary saphenous vein graft interventions in the drug-eluting stent era.
Pendyala LK, Loh JP, Kitabata H, Minha S, Torguson R, Chen F, Satler LF, Suddath WO, Pichard AD, Waksman R.
J Interv Cardiol. 2014 Aug;27(4):391-8. doi: 10.1111/joic.12136.
Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial.
Mehilli J, Pache J, Abdel-Wahab M, Schulz S, Byrne RA, Tiroch K, Hausleiter J, Seyfarth M, Ott I, Ibrahim T, Fusaro M, Laugwitz KL, Massberg S, Neumann FJ, Richardt G, Schömig A, Kastrati A; Is Drug-Eluting-Stenting Associated with Improved Results in Coronary Artery Bypass Grafts? (ISAR-CABG) Investigators.
Lancet. 2011 Sep 17;378(9796):1071-8. doi: 10.1016/S0140-6736(11)61255-5. Epub 2011 Aug 26.
Complete fracture of sirolimus-eluting stent in a saphenous vein graft to left anterior descending artery.
Yoo SH, Jin SW, Her SH, Yoon HJ, Kim HD, Im YS, Seung KB, Kim JH.
Korean Circ J. 2009 Jun;39(6):251-3. doi: 10.4070/kcj.2009.39.6.251. Epub 2009 Jun 30.
Comparison of diagnostic accuracy of immediate angiography derived residual quantitative flow ratio after bioresorbable scaffold and drug eluting stent implantation.
Li Z, Zhan J, Han J, Fu G, Jin C.
Rev Cardiovasc Med. 2022 Feb 12;23(2):59. doi: 10.31083/j.rcm2302059.
